FDA approves first 'biosimilar' to compete with Amgen chemotherapy drug

March 6, 2015 3:41 PM

14 0

The Food and Drug Administration approved the first copycat version of a biologic drug in the United States, allowing a Swiss company to sell a knockoff of Amgen Inc.’s chemotherapy recovery drug Neupogen.

The FDA authorized Novartis' Sandoz unit to sell its version of the Amgen drug in the United States. Sandoz intends to market it under the brand name Zarxio.

Read more

To category page